Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the founder of Hub Planner in connection with sale to Monterro
Mandate

Vinge advises the founder of Hub Planner in connection with sale to Monterro

November 24, 2022 Employment and Benefits M&A

Vinge has advised the founder Stephen Martin in relation to the sale of a majority of the shares in Hub Planner and its software platform for resource management to the private equity firm Monterro.

Hub Planner was founded in 2013 in Stockholm by the Irishman Stephen Martin. The company’s software platform is provided as SaaS-solution and focusses on resource scheduling, vacation and time off planning as well as timesheets. Hub Planner’s current customers include companies such as Mercedes, Havas and Pfizer, but the largest customer group is consultancy firms that with the help of the platform e.g. can plan and staff projects and report hours worked.

Vinge’s team consisted of Jonas Johansson and Carl Sander (M&A) and Sara Strandberg (Employment).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025